

1 **Cognitive change over one year among older adults with HIV and a low nadir CD4 cell count**

2

3 Marie-Josée Brouillette^{1,2}, Laurence Forcellino¹, Sybil Goulet-Stock³, Lesley K Fellows⁴, Lisa Koski¹, Marina B. Klein^{1,2}, Nancy E.
4 Mayo¹

5 ¹ Department of Psychiatry, McGill University Health Centre, Montreal, Québec

6 ² CIHR Canadian HIV Trials Network, Vancouver, British Columbia

7 ³ Psychology program, University of Victoria, Victoria, British Columbia

8 ⁴ Dept of Neurology & Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, Québec

9

10

11 Short title: Cognitive change in older adults with HIV

12 Competing Interests: the authors have no conflict of interest to report.

13

14

15

16

17

18 Abstract (291/300 words)

19
20 Background: Evidence regarding the risk of cognitive decline conferred by a low nadir CD4 cell count and increasing age in people
21 living with HIV is mixed. The objective of this study was to assess the change in cognition over one year among older adults with well-
22 controlled HIV infection and a history of low nadir CD4 cell count compared with the change in a matched non-HIV sample.

23 Methods: We recruited 50 HIV+ aviremic individuals 40 years or older, on stable antiretroviral treatment and with a nadir CD4 < 200
24 cells/ μ L, and seventeen matched HIV-negative individuals. Neuropsychological testing was performed twice, one year apart; an NPZ
25 was computed by averaging all z-scores and five existing algorithms for a diagnosis of HAND were applied. Change was defined as
26 making a reliable change on the NPZ or a change in HAND category (impaired vs not).

27 Results: Change in NPZ over one year was more often in the direction of an improvement, and not different between HIV+ and HIV-
28 individuals. Among the HIV+, the proportion meeting criteria for HAND at baseline ranged from 34-80% depending on the classification
29 algorithm. A reliable change in NPZ was demonstrated in a single HIV+ participant. In contrast, a transition between HAND category
30 at one year was common.

31 Conclusion: Among aviremic HIV+ older adults with a history of low nadir CD4 cell count, change in NPZ over 1 year was comparable
32 to that seen among demographically matched HIV- individuals and did not represent a reliable change while transition across HAND
33 category was common. Rates of HAND were very dependent on the classification algorithm applied. These findings provide some
34 explanation for the inconsistent findings from existing studies and highlight the importance of exercising caution when pooling results
35 in the field of neuroHIV.

36
37 **Key words:** HIV/AIDS, neurocognitive disorder, cognition, longitudinal studies, neuropsychological tests, aging

Background

39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59

While the introduction of combination antiretroviral therapy (cART) has been accompanied by a marked decrease in HIV-associated mortality and morbidity, HIV-related cognitive complications have persisted, with reported rates of HIV-Associated Neurocognitive Disorder (HAND) of 30-50% (1, 2). The presence of cognitive impairment, even mild, is associated with reduced occupational and social function, thus interfering with the attainment of the World Health Organization ‘4th 90 goal’ of achieving good health-related quality of life in at least 90% of those living with HIV (3-10).

Existing evidence suggests that people living with HIV who are well-treated show little decline in neuropsychological (NP) performance over time (11-16), although longitudinal data are sparse. However, it is unclear if this favorable course extends to those who are older, a group that also typically acquired HIV prior to the cART era, and thus tends to have low nadir CD4 cell counts. Evidence regarding the risk of cognitive decline conferred by a low nadir CD4 cell count and older age is mixed, with some studies reporting a lack of association (11, 13, 17-21) and others finding an increased risk of decline (16, 22-30). This question remains to be clarified: are older HIV+ individuals with a low nadir CD4 cell count at higher risk of cognitive decline than HIV-negative individuals of the same age? And do methodological differences between existing studies contribute to the discrepancy in the available evidence?

The objectives of this study are threefold: (i) to contribute evidence about the change in cognition over one year among older adults with well-controlled HIV infection and a history of low nadir CD4 cell count, compared to the change in a matched non-HIV sample; (ii) to provide evidence regarding the comparability of different measures of cognitive change used in the neuroHIV literature; and (iii) to contribute evidence to the validity of the classification algorithms by asking whether one of these algorithms applied at baseline provides a better prediction of the magnitude of change over the following year as measured by the NPZ. This was tested for several existing HAND classification algorithms as recent work from our group has found these yield very different rates of impairment (10).

60 Methods

61 Participants

62 Between June 2012 and May 2013, 50 clinically stable persons living with HIV were recruited among patients attending the Chronic
63 Viral Illness Service of the McGill University Health Centre in Montreal, Canada. Inclusion criteria were: 40 years or older, stable
64 antiretroviral regimen with an undetectable viral load for at least 6 months, and a nadir CD4 < 200 cells/ μ L. Exclusion criteria were:
65 history of dementia precluding consent or other neurological condition, current substance use disorder, change in psychoactive
66 medication within the last 2 months, poorly controlled Axis 1 psychiatric disorder and presence of hepatitis C infection, itself associated
67 with cognitive decline (18, 23, 31, 32). Seventeen HIV-negative individuals matched on variables important for neuropsychological
68 (NP) performance, namely sex, age, and education were recruited through advertisements in local gay magazines and community
69 organizations, and in common areas of the hospital.

71 Procedure/data collection

72 The local Research Ethics Board approved the protocol and all subjects provided informed consent. Clinical and socio-demographic
73 information was collected through an interview and a chart review. Participants completed NP testing on two occasions, one year apart.
74 Testing was performed by a trained research assistant, either in English or French, according to a manualized procedure to standardize
75 administration.

76 Measurement

77 We documented NP performance, presence of co-morbidities, and functional status.

78 Neuropsychological performance

79 Following current recommendations, the NP evaluation covered six cognitive domains, with ≥ 2 tests per domain (33). The test battery
80 was developed to support a diagnosis of HAND in Canada, in English and French. Senior neuropsychologists with experience testing in
81 both languages selected the most suitable tests and population norms: Hopkins Verbal Learning Test–Revised (HVLT-R) learning and

82 recall (34); Brief Visuospatial Memory Test-Revised (BVMT-R) learning and recall (35); Tower of London (36); Trail Making Test A
83 and B (TMT-A and B); Stroop (37); Letter/Number Sequencing, Symbol Search, Digit Symbol Coding (38); Spatial Span (39); Letter
84 and Category Fluency (37); Grooved Pegboard dominant and non-dominant hand (40). Alternate forms of the tests were used when
85 appropriate. Intelligence was assessed with the Toni-IV (41).

86 Co-morbid conditions

87 The presence and severity of co-morbid conditions that might preclude a diagnosis of HAND were systematically assessed in those with
88 HIV(42). The Hospital Anxiety and Depression Scale (HADS) was used to screen for the presence of clinically important anxiety and
89 depression(43, 44), with a score ≥ 8 on either scale considered clinically significant, complemented by clinical judgement during testing.
90 Alcohol use was evaluated with the AUDIT-C(45, 46), type and frequency of substances used was assessed by a questionnaire and
91 complemented by a urine toxicology screen. History of CNS opportunistic infection, presence of non-HIV neurological conditions,
92 developmental disability and current systemic disease were documented by chart review. The severity of co-morbid conditions was rated
93 as compatible or contributing according to the guidelines from the 2007 updated research nosology for HAND(33); confounding
94 conditions were excluded. In the HIV-negative group, we documented depression, anxiety and cognitive difficulties.

95 Function

96 Function was assessed with several instruments. In both groups, instrumental activities of daily living (IADL) was assessed with the
97 Older Americans Resources and Services Social Resources Scale (OARS) IADL(47) and the presence of cognitive difficulties in
98 everyday life was documented with the self-reported Perceived Deficit Questionnaire (PDQ), scored 0-80, with a score > 40 indicative
99 of important difficulties (48). In HIV+, adherence was assessed with the Simplified Medication Adherence Questionnaire (SMAQ) and
100 poor adherence was defined as a positive response to any of the qualitative questions (ever forget to take medicine, careless at times
101 about taking your medicine, stop taking medicine when feels worse, failing to take medicine over past week-end), more than two doses
102 missed over the past week, or over 2 days of total non-medication during the past 3 months (49).

103 Data analysis

104
105 Raw scores on neuropsychological tests were converted to demographically corrected z-scores. Overall NP performance was assessed
106 by the NPZ, calculated by averaging z-scores from all tests, with a lower score indicating worse cognition and a positive value on the
107 change score reflecting an improvement in overall NP performance.

108 Several algorithms for the diagnosis of HAND in current use in neuro-HIV research were applied. While all algorithms require
109 impairment in ≥ 2 cognitive domains, these methods differ in their definition of domain impairment: Method A: Lowest z-score per
110 domain is > 1 S.D. below norms (50, 51); Method B: Lowest z-score per domain is > 1.5 S.D. below norms (52); Method C: Average
111 z-score for all tests in a specific domain ≥ 1.5 S.D. below norms (53); Method D: one z-score > 1.5 S.D. below norms or 2 tests > 1
112 S.D. below norms in a domain (54); and Clinical Rating, described elsewhere (55, 56). The classification algorithms were applied to
113 HIV+ and HIV- participants to classify them as cognitively impaired (i.e., compatible with a neurocognitive disorder—presumptively
114 HAND in the case of those with HIV) or not.

115 Change over one year was defined in two ways: as a change in NPZ or a transition across HAND classification (impaired vs not). We
116 also used Reliable Change Index (RCI) to identify participants who, over the course of one year, made a meaningful change in NPZ
117 value; the RCI is the difference between two assessments divided by a factor related to the standard deviation of each measurement time
118 point and their correlation.

119 Comparisons were made using 2-sided Fisher's exact test for variables presented dichotomous, t-test for means of continuous variables
120 deemed normally distributed, with pooled or Satterthwaite variance calculations depending on whether or not the variances were deemed
121 unequal, and Mood's median test for continuous variables that did not follow a normal distribution.

122 Distributional parameters were used to characterize the sample and to compare HIV+ and HIV- participants. People were compared on
123 NPZ values at baseline and follow-up by HIV status (HIV+, HIV-) and availability of follow-up data. The proportion of participants
124 classified as impaired (HAND) according to each classification algorithm was calculated, and stability over time was calculated for each

125 participant. As the sample size was small, p-values would not necessarily indicate important differences in proportions of participants
 126 impaired. Rather, we used the criterion measure of 10% difference in proportion classified as impaired between HIV+ and HIV- across
 127 classification methods and at each time point (57). We used Reliable Change Index (RCI) to identify participants who, over the course
 128 of one year, made a meaningful change in NPZ value and tested its association with impairment status according to each classification
 129 algorithm at baseline.

130 RESULTS

131 Table 1 shows the personal and clinical characteristics of the sample at the baseline visit.

132
 133 Table 1 Personal and clinical characteristics in HIV-positive and HIV-negative participants at the baseline visit

134

Variable	HIV+ (n=50)	HIV- (n=17)	p value of difference in means or medians
Demographics	Mean (SD), Median (IQR) or N (%)	Mean (SD), Median (IQR) or N (%)	
Sex, male, N (%)	46 (92)	14 (82)	0.36
Age (years), mean (SD)	53 (7)	53 (7)	0.92
Education (years), mean (SD)	16 (4)	16 (4)	0.90
Ethnicity, Caucasian, N (%)	38 (76)	16 (94)	0.16
Language, French, N (%)	38 (76)	11 (65)	0.36
Clinical variables			
Duration of HIV infection (years), mean (SD)	16.4 (7.3)		
Current CD4+ (cells/ μ L), median (IQR)	425.5 (338-648)		
Nadir CD4+ (cells/ μ L), median (IQR)	86 (32-143)		
HADS ^a depression score (0-21)			

median (IQR)	4 (2-6)	3 (1-5)	0.47
depressed (≥ 8), N (%)	7 (14)	2 (12)	1.00
HADS ^a anxiety score (0-21)			
median (IQR)	6 (5-8)	6 (4-9)	0.94
anxious (≥ 8), N (%)	19 (38)	5 (29)	0.57
Overall NP performance			
NPZ at baseline, mean (SD)	-0.42 (0.61)	-0.28 (0.97)	0.59
Functional impact			
Any impairment in IADL, N (%) ^d	3 (6)	0	
Poor medication adherence (SMAQ ^b), N (%)	33 (66)		
PDQ ^c scores (0-80), mean (SD)	25.4 (13.0)	21.1 (10.3)	0.21
PDQ > 40, N (%)	5 (10)	0	0.32

- 135 ^a Hospital Anxiety and Depression Scale
- 136 ^b Simplified Medication Adherence Questionnaire
- 137 ^c Perceived Deficit Questionnaire
- 138 ^d Instrumental Activities of Daily Living, Older Americans Resources and Services Social Resources Scale (OARS)

139

140 [Comparison of overall cognition, mood and function among HIV+ and HIV- participants at baseline](#)

141 The HIV+ participants were generally well-educated Caucasian males in their mid-50s, who had been living with HIV for a mean of

142 16.4 years (range: 2.2 - 26.6 years) at study entry. Current CD4 cell count was in the normal range and nadir CD4 was low at a median

143 of 86 cells/ μ L, per design. The HIV negative participants were well-matched (3:1) on age, sex, and education. The proportion with

144 clinically important anxiety was high among HIV+ and HIV- groups (38% and 29% respectively); the proportion with depression was

145 lower (HIV+: 14%, HIV-: 12%). At baseline, NPZ scores in HIV+ and HIV- groups were not different. Baseline intelligence was within

146 the normal range in all study participants.

147 Function at baseline was intact in all HIV- individuals. Among HIV+ participants, one participant reported requiring some help in
 148 handling his money, one needing some assistance to do housework and a single participant reported difficulties in two areas, doing
 149 housework and preparing meals. Five HIV+ participants endorsed the presence of important cognitive difficulties, including the
 150 participant who needed some help to manage finances and the participant who had limitations in both housework and meal preparation.
 151 Difficulties with adherence were surprisingly high in this aviremic sample, with 66% reporting some difficulties, mostly with a positive
 152 reply to the question “Do you ever forget to take your medicine”. The presence of co-morbid conditions was rated as potentially
 153 contributing to cognitive difficulties for two HIV+ individuals with a known attention deficit disorder but no potentially confounding
 154 condition was present in any participant.

155 [Comparison of overall cognition at 1 year according to HIV status and availability of follow-up data](#)

156 Follow-up at one year was completed by 43/50 HIV+ and 12/17 HIV- participants. Table 2 shows the comparison of the baseline NPZ
 157 between those who were retested at 1 year versus those who were not, and between HIV+ and HIV- groups.

158 Table 2 Comparison of the baseline and follow-up NPZ between those with follow-up at 1 year and those without

159

	Mean NPZ (SD)			
	HIV+		HIV-	
	N	NPZ, means (SD)	N	NPZ, means (SD)
NPZ at baseline, comparison of participants with and without follow-up				
All, baseline NPZ	50	-0.42 (0.61)	17	-0.28 (0.97)
Without follow-up, baseline NPZ	7	-0.73 (0.67)	5	-0.63 (0.99)
With follow-up, baseline NPZ	43	-0.37 (0.59)	12	-0.14 (0.96)
Difference in mean NPZ at baseline between those with and without FU ^a	50	0.36 (0.60) 95% CI: -0.13, 0.86 p=0.15	17	0.49 (0.97) 95% CI: -0.61, 1.59 p=0.36

	NPZ at 1 year, comparison of HIV+ and HIV- participants			
With follow-up, NPZ at 1 year	43	-0.25 (0.52)	12	0.04 (1.00)
Mean difference in NPZ at follow-up minus baseline	43	0.12 (0.32) 95% CI: 0.02, 0.22 p=0.02	12	0.18 (0.31) 95% CI: -0.01, 0.38 p=0.06
Difference HIV+ to HIV- at follow-up	-0.06 (0.32), 95% CI: (-0.27, 0.15) p=0.54			

160 ^a T-test, p-values from t-tests with pooled variance

161

162 Among HIV+ and HIV-, those who were not retested at 1 year were more impaired at baseline than those who were, but the difference
163 was not significant. Change in overall NP performance over one year as measured by the change in NPZ was not different between
164 HIV+ and HIV- participants, with both groups showing a slight improvement in the NPZ at follow-up. The analyses were repeated using
165 the last value carried forward for those missing follow-up; the results remained unchanged (data not shown).

166 [Comparison of HAND classification and associated change in NPZ, at baseline and 1 year according to HIV status](#)
167 On NP tests, missing data were minimal except for the Stroop test that could not be completed by seven participants who were color-
168 blind. Table 3 shows the proportion of participants who met impairment criteria for each HAND classification algorithm and evolution
169 over 1 year, according to HIV status. Assigning all missing data as impaired did not change the classification of impairment for any
170 participant.

171

172 Table 3 Proportion of participants who met impairment criteria for each HAND classification algorithm and evolution over 1 year,
173 with shaded boxes representing a change in classification between impaired (HAND) versus not.

174

Method	Impairment status at baseline		Impairment status at follow-up		
	Status	N (%)	Impaired	Normal	Missing
	HIV+ (n=50)				
A	Impaired	40 (80.0 %)	29 (72.5 %)	6 (15.0 %)	5 (12.5%)
	Normal	10 (20.0 %)	3 (30.0 %)	5 (50.0 %)	2 (20.0%)
B	Impaired	31 (62.0 %)	18 (58.1 %)	8 (25.8 %)	5 (16.1%)
	Normal	19 (38.0 %)	4 (21.1 %)	13 (68.4 %)	2 (10.5%)
C	Impaired	17 (34.0 %)	4 (23.5 %)	9 (52.9 %)	4 (23.5%)
	Normal	33 (66.0 %)	1 (3.0 %)	29 (87.9 %)	3 (9.1%)
D	Impaired	30 (60.0 %)	17 (56.7 %)	8 (26.7 %)	5 (16.7 %)
	Normal	20 (40.0 %)	5 (25.0 %)	13 (65.0 %)	2 (10.0 %)
Clinical Rating	Impaired	37 (74.0 %)	21(56.8 %)	10 (27.0 %)	6 (16.2%)
	Normal	13 (26.0 %)	6 (46.2 %)	6 (46.2 %)	1 (7.7%)
	HIV- (n=17)				
A	Impaired	10 (58.8%)	4 (40.0 %)	2 (20.0 %)	4 (40.0%)
	Normal	7 (41.2 %)	1 (14.3 %)	5 (71.4%)	1 (14.3%)
B	Impaired	6 (35.3 %)	4 (66.7 %)	0	2 (33.3%)

	Normal	11 (64.7 %)	0	8 (72.7 %)	3 (27.3%)
C	Impaired	5 (29.4 %)	2 (40.0 %)	1 (20.0 %)	2 (40.0%)
	Normal	12 (70.6 %)	0	9 (75.0 %)	3 (25.0%)
D	Impaired	7 (41.2 %)	4 (57.1 %)	0	3 (42.9 %)
	Normal	10 (58.8 %)	0	8 (80.0 %)	2 (20.0 %)
Clinical Rating	Impaired	8 (47.1 %)	4 (50.0 %)	0	4 (50.0 %)
	Normal	9 (52.9 %)	1 (11.1 %)	7 (77.8 %)	1
Difference in proportion impaired between HIV+ and HIV- at baseline and follow-up					
A	HIV+ greater impairment %		HIV+ greater impairment %		
B	HIV+ greater impairment %		HIV+ and HIV- similar %		
C	Similar impairment %		HIV+ greater impairment %		
D	HIV+ greater impairment %		HIV+ and HIV- similar %		
Clinical Rating	HIV+ greater impairment %		Similar impairment %		

Method A: Lowest score per domain is > 1 S.D. below norms.

Method B: Lowest score per domain is > 1.5 S.D. below norms

Method C: Average of all z-scores \geq 1.5 S.D. below norms

Method D: 1 > 1.5 S.D. below norms or 2 tests > 1. S.D. below norms

175

176

177 Among HIV+ individuals, the proportion of impairment at baseline ranged from 34 % (Method C) to a high of 80 % (Method A). The
178 rate of neurocognitive impairment according to these criteria was also high among HIV- participants, ranging from 29.4 % (Method C)
179 to 58.8 % (Method A). Change in impairment status over the follow-up period was quite common and was more often in the direction
180 of improvement, with a transition from impaired to unimpaired. Among the HIV+, the highest stability in impairment classification was
181 seen among those who were classified as normal according to Method C, with 87.9 % remaining normal at follow-up. At the other end
182 of the spectrum, as many as 52.9 % of those classified as impaired at baseline by the same method were classified as normal at follow-
183 up. At baseline, using our criterion measure of a difference of 10%, Methods A, B, D and CR identified people with HIV+ to have a
184 higher prevalence of impairment than people who were HIV-; one year later, only Methods A and C distinguished the two groups.
185 Classification Method A was the only method that consistently distinguished between HIV+ from HIV- over time.
186 Figure 1 shows the change in NPZ over 1 year for each HAND classification at baseline, with bars in the boxes representing those who
187 were classified as impaired at baseline.
188
189

190 Figure 1 Average change in NPZ according to impairment and HIV status for different classification methods

191

192 Declines in NPZ were seen only in HIV+ participants classified as unimpaired at baseline and were greater for those classified as

193 impaired by Methods A and Clinical Rating, but the magnitude of the decline was small, one-tenth of a SD, thus probably not

194 clinically important (58). Improvement in NPZ was seen in several groups, but never exceeded one-third of a SD. No diagnostic

195 algorithm emerged as being clearly superior in predicting the magnitude of cognitive decline at 1 year.

196 In contrast to the common change in HAND classification, only a single HIV+ participant made a reliable change on the NPZ, so no

197 analysis of association with diagnostic classification was conducted.

198

199 CONCLUSIONS

200 Among aviremic HIV+ older adults with a history of low nadir CD4 cell count, change in overall NP performance over one year was

201 comparable to that seen among matched HIV- individuals, and a single HIV+ participant made a reliable change on that measure. This

202 is excellent news for survivors of the pre-cART era, adding further evidence that such individuals generally show a trajectory of cognitive

203 change comparable to that of their age- and education-matched HIV- counterparts, at least over the short term.

204 The application of various existing algorithms for the operationalization of the HAND diagnostic criteria resulted in proportions of

205 impairment at baseline ranging from 34 to 80 % among the HIV+, and from 29.4 to 58.8% among HIV- participants (see Table 3). Four

206 of the five classifications algorithms showed greater prevalence of impairment (> 10% in prevalence) for HIV+ participants compared

207 to HIV-. At follow-up, only classification A distinguished these two groups on prevalence of impairment. Classification A also assigned
208 the greatest proportion of people as impaired at baseline, 80 % for HIV+ and 58.8% for HIV-, raising concerns about the possibility of
209 overdiagnosis.

210 Change in HAND classification among those with HIV was common in our sample for all classification methods, as was previously
211 seen in studies using a more limited number of methods (16, 59, 60). None of the tested HAND classification algorithms emerged as
212 being superior in identifying those whose cognition will decline over the following year but this is not surprising as, in our sample,
213 improvement in NPZ scores was much more common than decline; decline, when present, was very small and far less than the 0.5 SD
214 usually considered indicative of meaningful change (58). The observed improvement in NPZ scores is likely due to a combination of
215 regression to the mean and practice effects, despite the use of alternate forms of some cognitive tests. The modest changes in NPZ values
216 were often accompanied by a change in HAND classification status. This illustrates the high risk of misclassification associated with
217 use of a binary classification system, especially when individuals are close to the cut-off scores, as seems to have been the case here;
218 this lends support to the recommendation to analyze performance on cognitive tests as a continuous variable in research studies (16, 61).
219 Alternative approaches to identification of cognitive phenotypes of brain involvement are emerging (20) and may shed a new light on
220 the understanding of HIV's impact on the brain.

221 Our findings do not completely exclude the possibility that progressive brain dysfunction does take place at a higher rate among
222 selected HIV+ individuals than among matched HIV- individuals. Our measure of overall NP performance, the NPZ, was selected for

223 its sensitivity to a decline of performance in the normal range, in contrast to alternative measures used in neuroHIV research such as the
224 Global Deficit Score (GDS)(62). Despite the selection of this sensitive measure, over a one-year period, we have seen little evidence of
225 neurocognitive decline and a reliable change occurred in a single participant. Brain imaging may provide more sensitive biomarkers for
226 brain changes, although at least some longitudinal data argue that brain atrophy in those with HIV infection on cART does not progress
227 faster than in age-matched controls (63-65), and longer follow-up periods are needed.

228 Our study adds to the limited evidence regarding the risk for cognitive decline associated with a low nadir CD4 cell count among well-
229 treated HIV+ individuals. A study of middle-aged clinically stable HIV+ individuals (88% aviremic) in Australia found that cognitive
230 decline over an 18-month period, as measured by the Global Change Score approach, did not differ statistically between 96 HIV+ and
231 44 matched HIV-subjects; while a low nadir CD4 cell count was not an inclusion criteria for their HIV+ participants, the mean value
232 was low, at 181 cells/ μ L(17). Similarly, in the Multicenter AIDS Cohort Study (MACS), 77% of gay/bisexual male participants on
233 cART with virologic suppression followed over 4 years did not show a progression across HAND categories, and a low nadir CD4 cell
234 count was not associated with an increased risk for HAND progression.

235 In this study, we classified individuals as impaired (HAND) or not, and did not make a distinction between asymptomatic neurocognitive
236 impairment (ANI) and mild neurocognitive disorder (MND), even though information about function was available. The distinction
237 between ANI and MND hinges on the degree of impairment in activities of daily living but the methods used to assess function vary
238 across research groups and can result in important disparities in those classified as ANI and MND (66). Here, to avoid this

239 methodological problem, the information about function was used to characterize the sample and those with ANI and MND were
240 combined in a category of ‘impaired’. The rate of self-reported functional impairment in the HIV+ group was low except with regards
241 to self-reported adherence. This finding is surprising as all participants were aviremic; however, the importance of these reported
242 difficulties should not be underestimated as good virological control at study entry does not exclude the possibility of viral blips that
243 can have a detrimental effect on disease progression (67).

244 Our study contributes important information about the impact of the operationalization of cognitive change. Here, we confirm our
245 previous finding that algorithms used by various research groups identify very different groups of individuals (10), such that great
246 caution has to be exercised in comparing findings. This methodological aspect likely contributes to inconsistent findings across studies
247 and constitutes an important impediment to the pooling of data that is necessary for the field to move forward.

248 One of the strengths of our study is the presence of a demographically matched HIV- group. This allows us to determine if the cognitive
249 decline is greater than expected based on age, education, and lifestyle factors. In the current test-and-treat era, among those with access
250 to cART, the majority of HIV+ individuals have an undetectable viral load. Are those people different from their HIV- counterparts?
251 We find that the role of historical HIV clinical markers may be limited, echoing the conclusion of Bonnet et al. that, among participants
252 in the Aquitaine cohort, the presence of cognitive impairment was not related to HIV nor cART-related variables (50).

253 Our sample, by design, is not representative of all older HIV+ individuals. It represents a group of special clinical interest, individuals
254 who are well treated and aviremic but present a history of low nadir CD4 cell count. Rates of neurocognitive impairment in this study

255 are high, 34-80 %. While bearing in mind the challenges in comparing studies mentioned above, these rates are comparable to those
256 reported elsewhere. Among 1525 participants in the CHARTER cohort, 39% had HAND. In the NEAD cohort (68) that also selected
257 individuals with a CD4 count <200 cells/ μ L, Sacktor reported a rate of impairment of 76%, defined by overall neuropsychologist's
258 impression: however, 77% of the participants had a detectable viremia. Wojna reported a prevalence of HIV-associated cognitive
259 impairment of 77.6% in a group of 49 HIV+ Hispanic women in Puerto Rico who had a nadir CD4 cell count of \leq 500 cells/ μ l (69). Of
260 note, the rates of impairment in our HIV- participants were high as well, a finding reported by others that raises important questions
261 about the validity of current HAND definitions (70-72) .

262 This study has limitations. The control sample was small as it was difficult to recruit normal subjects for this type of testing. In addition,
263 the follow-up period of 1 year was short and, as is usual, there was some loss to follow-up over a year. Those who were not retested at
264 1 year in the HIV+ and HIV- had lower cognition at baseline than those who were retested; although the difference was potentially
265 meaningful, it was not statistically significant with this sample size. This indicates that in longitudinal studies, those who are most
266 impaired are challenging to retain, with important implications for the results.

267 In conclusion, in a sample of aviremic HIV+ individuals at potentially higher risk of cognitive impairment as a consequence of older
268 age and nadir CD cell count < 200 cells/ μ L, the prevalence of HAND ranged from 34-80% depending on the criteria used for
269 classification. Functional impairment was very mild and change in NPZ over one year was not different than that of matched HIV-
270 individuals. The finding that cognitive decline is not inevitable, at least over the short term, is encouraging for persons living with HIV

271 who dread the development of progressive cognitive impairment as they age. It argues for encouraging people with HIV to adhere to
272 cART and to recommendations to maintain brain health for the general adult population such as smoking cessation, regular physical
273 activity and optimal control of glucose and lipids.

274

275 Acknowledgement: This study was supported by the CIHR Canadian HIV Trials Network (CTNPT 005). We express our gratitude to
276 the study participants.

277

278 References

279


- 280 1. Cysique LA, Brew BJ. Prevalence of non-confounded HIV-associated neurocognitive impairment in the context of plasma HIV RNA
281 suppression. *Journal of neurovirology*. 2011;17(2):176-83.
- 282 2. Heaton RK, Clifford DB, Franklin DR, Jr., Woods SP, Ake C, Vaida F, et al. HIV-associated neurocognitive disorders persist in the era of potent
283 antiretroviral therapy: CHARTER Study. *Neurology*. 2010;75(23):2087-96.
- 284 3. Jia H, Uphold CR, Wu S, Reid K, Findley K, Duncan PW. Health-related quality of life among men with HIV infection: effects of social support,
285 coping, and depression. *AIDS patient care and STDs*. 2004;18(10):594-603.
- 286 4. Letendre SL, McCutchan JA, Childers ME, Woods SP, Lazzaretto D, Heaton RK, et al. Enhancing antiretroviral therapy for human
287 immunodeficiency virus cognitive disorders. *Annals of neurology*. 2004;56(3):416-23.
- 288 5. Power C, Boisse L, Rourke S, Gill MJ. NeuroAIDS: an evolving epidemic. *Can J Neurol Sci*. 2009;36(3):285-95.
- 289 6. Price RW, Yiannoutsos CT, Clifford DB, Zaboriski L, Tselis A, Sidtis JJ, et al. Neurological outcomes in late HIV infection: adverse impact of
290 neurological impairment on survival and protective effect of antiviral therapy. AIDS Clinical Trial Group and Neurological AIDS Research Consortium
291 study team. *AIDS*. 1999;13(13):1677-85.
- 292 7. Tozzi V, Balestra P, Galgani S, Murri R, Bellagamba R, Narciso P, et al. Neurocognitive performance and quality of life in patients with HIV
293 infection. *AIDS research and human retroviruses*. 2003;19(8):643-52.
- 294 8. Vivithanaporn P, Heo G, Gamble J, Krentz HB, Hoke A, Gill MJ, et al. Neurologic disease burden in treated HIV/AIDS predicts survival: a
295 population-based study. *Neurology*. 2010;75(13):1150-8.
- 296 9. Ellis RJ, Rosario D, Clifford DB, McArthur JC, Simpson D, Alexander T, et al. Continued high prevalence and adverse clinical impact of human
297 immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study. *Arch Neurol*.
298 2010;67(5):552-8.
- 299 10. Brouillette MJ, Koski L, Forcellino L, Gasparri J, Brew BJ, Fellows LK, et al. Predicting occupational outcomes from neuropsychological test
300 performance in older people with HIV. *AIDS*. 2021;35(11):1765-74.
- 301 11. Sacktor N, Skolasky RL, Seaberg E, Munro C, Becker JT, Martin E, et al. Prevalence of HIV-associated neurocognitive disorders in the
302 Multicenter AIDS Cohort Study. *Neurology*. 2016;86(4):334-40.
- 303 12. Qu Y, Weinstein A, Wang Z, Cheng Y, Kingsley L, Levine A, et al. Legacy effect on neuropsychological function in HIV-infected men on
304 combination antiretroviral therapy. *AIDS*. 2022;36(1):19-27.
- 305 13. Yuen T, Brouillette MJ, Fellows LK, Ellis RJ, Letendre S, Heaton R, et al. Personalized Risk Index for Neurocognitive Decline Among People
306 With Well-Controlled HIV Infection. *Journal of acquired immune deficiency syndromes*. 2017;76(1):48-54.
- 307 14. Evering TH, Applebaum A, La Mar M, Garmon D, Dorfman D, Markowitz M. Rates of non-confounded HIV-associated neurocognitive
308 disorders in men initiating combination antiretroviral therapy during primary infection. *AIDS*. 2016;30(2):203-10.

- 309 15. Chan P, Kerr SJ, Kroon E, Colby D, Sacdalan C, Hellmuth J, et al. Cognitive trajectories after treatment in acute HIV infection. *AIDS*. 2021;35(6):883-8.
- 310
- 311 16. Damas J, Ledergerber B, Nadin I, Tarr PE, Stoeckle M, Kunze U, et al. Neurocognitive course at two-year follow-up in the neurocognitive
312 assessment in the metabolic and aging cohort (NAMACO) study. *AIDS*. 2021.
- 313 17. Gott C, Gates T, Dermody N, Brew BJ, Cysique LA. Cognitive change trajectories in virally suppressed HIV-infected individuals indicate high
314 prevalence of disease activity. *PloS one*. 2017;12(3):e0171887.
- 315 18. Sheppard DP, Woods SP, Bondi MW, Gilbert PE, Massman PJ, Doyle KL, et al. Does older age confer an increased risk of incident
316 neurocognitive disorders among persons living with HIV disease? *The Clinical neuropsychologist*. 2015;29(5):656-77.
- 317 19. Becker JT. Prevalence of cognitive disorders differs as a function of age in HIV virus infection. *Aids*. 2004;18:11.
- 318 20. Paul RH, Cho K, Belden A, Carrico AW, Martin E, Bolzenius J, et al. Cognitive Phenotypes of HIV Defined Using a Novel Data-driven Approach.
319 *Journal of Neuroimmune Pharmacology*. 2022:1-11.
- 320 21. Aung HL, Aghvinian M, Gouse H, Robbins RN, Brew BJ, Mao L, et al. Is There Any Evidence of Premature, Accentuated and Accelerated
321 Aging Effects on Neurocognition in People Living with HIV? A Systematic Review. *AIDS and behavior*. 2021;25(3):917-60.
- 322 22. Ellis RJ, Badiie J, Vaida F, Letendre S, Heaton RK, Clifford D, et al. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of
323 combination antiretroviral therapy. *AIDS*. 2011;25(14):1747-51.
- 324 23. Oliveira NL, Kennedy EH, Tibshirani R, Levine A, Martin E, Munro C, et al. Longitudinal 5-year prediction of cognitive impairment among
325 men with HIV disease. *AIDS*. 2021;35(6):889-98.
- 326 24. Robertson KR, Smurzynski M, Parsons TD, Wu K, Bosch RJ, Wu J, et al. The prevalence and incidence of neurocognitive impairment in the
327 HAART era. *AIDS (London, England)*. 2007;21(14):1915-21.
- 328 25. Aung HL, Bloch M, Vincent T, Quan D, Jayewardene A, Liu Z, et al. Cognitive ageing is premature among a community sample of optimally
329 treated people living with HIV. *HIV medicine*. 2021;22(3):151-64.
- 330 26. Aung HL, Gates TM, Mao L, Brew BJ, Rourke SB, Cysique LA. Abnormal cognitive aging in people with HIV: Evidence from Data Integration
331 between two countries' cohort studies. *AIDS (London, England)*. 2022.
- 332 27. Goodkin K, Miller EN, Cox C, Reynolds S, Becker JT, Martin E, et al. Effect of ageing on neurocognitive function by stage of HIV infection:
333 evidence from the Multicenter AIDS Cohort Study. *The lancet HIV*. 2017;4(9):e411-e22.
- 334 28. Maki PM, Rubin LH, Valcour V, Martin E, Crystal H, Young M, et al. Cognitive function in women with HIV: findings from the Women's
335 Interagency HIV Study. *Neurology*. 2015;84(3):231-40.
- 336 29. Garvey L, Surendrakumar V, Winston A. Low rates of neurocognitive impairment are observed in neuro-asymptomatic HIV-infected
337 subjects on effective antiretroviral therapy. *HIV clinical trials*. 2011;12(6):333-8.
- 338 30. Gawron N, Choiński M, Szymańska-Kotwica B, Pluta A, Sobańska M, Egbert A, et al. Effects of age, HIV, and HIV-associated clinical factors
339 on neuropsychological functioning and brain regional volume in HIV+ patients on effective treatment. *Journal of neurovirology*. 2019;25(1):9-21.

- 340 31. Molsberry SA, Lecci F, Kingsley L, Junker B, Reynolds S, Goodkin K, et al. Mixed membership trajectory models of cognitive impairment in
341 the multicenter AIDS cohort study. *AIDS*. 2015;29(6):713-21.
- 342 32. Grant I, Franklin DR, Jr., Deutsch R, Woods SP, Vaida F, Ellis RJ, et al. Asymptomatic HIV-associated neurocognitive impairment increases
343 risk for symptomatic decline. *Neurology*. 2014;82(23):2055-62.
- 344 33. Antinori A. Updated research nosology for HIV-associated neurocognitive disorders. *Neurology*. 2007;69(18):1789.
- 345 34. Brandt J, Benedict RH. Hopkins verbal learning test--revised: professional manual. Lutz, FL: Psychological Assessment Resources; 2001.
- 346 35. Benedict RHB, Schretlen D, Groninger L, Dobraski M, Melissa, et al. Revision of the Brief Visuospatial Memory Test: Studies of normal
347 performance, reliability, and validity. *Psychological assessment*. 1996;8(2):145-53.
- 348 36. Culbertson WC, Zillmer EA. Tower of London Drexel University (TOL DX), second edition. Toronto, Canada: Multi-Health Systems; 2005.
- 349 37. Delis DC, Kaplan E, Kramer JH. Delis-Kaplan executive function system: The Psychological Corporation; 2001.
- 350 38. Wechsler D. Wechsler Adult Intelligence Scale--Fourth Edition: Canadian Technical Manual. Toronto, Ontario: Pearson Canada; 2008.
- 351 39. Lafayette Instrument Grooved Pegboard Test: Lafayette Instrument Company; 2002.
- 352 40. Heaton R, Miller SW, Taylor MJ, Grant I. Revised comprehensive norms for an expanded Halstead-Reitan Battery: Demographically
353 adjusted neuropsychological norms for African American and Caucasian adults. Lutz, FL: Psychological Assessment Resources. 2004.
- 354 41. Brown L, Sherbenou RJ, Johnsen SK. Test of Nonverbal Intelligence, Fourth Edition (TONI-4). Austin, TX2010.
- 355 42. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, et al. Updated research nosology for HIV-associated neurocognitive
356 disorders. *Neurology*. 2007;69(18):1789-99.
- 357 43. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta psychiatrica Scandinavica*. 1983;67(6):361-70.
- 358 44. Olsson I, Mykletun A, Dahl AA. The Hospital Anxiety and Depression Rating Scale: a cross-sectional study of psychometrics and case finding
359 abilities in general practice. *BMC Psychiatry*. 2005;5:46.
- 360 45. Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening
361 test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. *Archives of internal*
362 *medicine*. 1998;158(16):1789-95.
- 363 46. Bradley KA, Bush KR, Epler AJ, Dobie DJ, Davis TM, Sporleder JL, et al. Two brief alcohol-screening tests From the Alcohol Use Disorders
364 Identification Test (AUDIT): validation in a female Veterans Affairs patient population. *Archives of internal medicine*. 2003;163(7):821-9.
- 365 47. Fillenbaum GG. Screening the elderly. A brief instrumental activities of daily living measure. *Journal of the American Geriatrics Society*.
366 1985;33(10):698-706.
- 367 48. Sullivan JLL, Edgley, K., Dehoux, E. A survey of multiple sclerosis. Part 1: Perceived cognitive problems and compensatory strategy use.
368 *Canadian Journal of Rehabilitation*. 1990;4:99-105.
- 369 49. Knobel H, Alonso J, Casado JL, Collazos J, Gonzalez J, Ruiz I, et al. Validation of a simplified medication adherence questionnaire in a large
370 cohort of HIV-infected patients: the GEEMA Study. *AIDS*. 2002;16(4):605-13.

- 371 50. Bonnet F, Amieva H, Marquant F, Bernard C, Bruyand M, Dauchy FA, et al. Cognitive disorders in HIV-infected patients: are they HIV-
372 related? *AIDS*. 2013;27(3):391-400.
- 373 51. McDonnell J, Haddow L, Daskalopoulou M, Lampe F, Speakman A, Gilson R, et al. Minimal cognitive impairment in UK HIV-positive men
374 who have sex with men: effect of case definitions and comparison with the general population and HIV-negative men. *Journal of acquired immune*
375 *deficiency syndromes (1999)*. 2014;67(2):120-7.
- 376 52. Gisslen M, Price RW, Nilsson S. The definition of HIV-associated neurocognitive disorders: are we overestimating the real prevalence? *BMC*
377 *infectious diseases*. 2011;11:356.
- 378 53. Meyer AC, Boscardin WJ, Kwasa JK, Price RW. Is it time to rethink how neuropsychological tests are used to diagnose mild forms of HIV-
379 associated neurocognitive disorders? Impact of false-positive rates on prevalence and power. *Neuroepidemiology*. 2013;41(3-4):208-16.
- 380 54. Gates TM, Cysique LA. The Chronicity of HIV Infection Should Drive the Research Strategy of NeuroHIV Treatment Studies: A Critical Review.
381 *CNS drugs*. 2016;30(1):53-69.
- 382 55. Heaton RK, Kirson D, Velin RA, Grant I, Group. tH. The utility of clinical ratings for detecting early cognitive change in HIV infection (pp.
383 188-206). In: Martin IGA, editor. *Neuropsychology of HIV infection: Current research and new directions*. New York: Oxford University Press; 1994.
- 384 56. Woods SP, Rippeth JD, Frol AB, Levy JK, Ryan E, Soukup VM, et al. Interrater reliability of clinical ratings and neurocognitive diagnoses in
385 HIV. *Journal of clinical and experimental neuropsychology*. 2004;26(6):759-78.
- 386 57. Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research.
387 *Communications in statistics-simulation and computation*. 2009;38(6):1228-34.
- 388 58. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard
389 deviation. *Medical care*. 2003;41(5):582-92.
- 390 59. Tierney SM, Sheppard DP, Kordovski VM, Faytell MP, Avci G, Woods SP. A comparison of the sensitivity, stability, and reliability of three
391 diagnostic schemes for HIV-associated neurocognitive disorders. *Journal of neurovirology*. 2017;23(3):404-21.
- 392 60. Heaton RK, Franklin DR, Jr., Deutsch R, Letendre S, Ellis RJ, Casaletto K, et al. Neurocognitive change in the era of HIV combination
393 antiretroviral therapy: the longitudinal CHARTER study. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of*
394 *America*. 2015;60(3):473-80.
- 395 61. Nightingale S, Dreyer AJ, Saylor D, Gisslén M, Winston A, Joska JA. Moving on From HAND: Why We Need New Criteria for Cognitive
396 Impairment in Persons Living With Human Immunodeficiency Virus and a Proposed Way Forward. *Clinical Infectious Diseases*. 2021;73(6):1113-8.
- 397 62. Carey CL, Woods SP, Gonzalez R, Conover E, Marcotte TD, Grant I, et al. Predictive validity of global deficit scores in detecting
398 neuropsychological impairment in HIV infection. *Journal of clinical and experimental neuropsychology*. 2004;26(3):307-19.
- 399 63. Sanford R, Strain J, Dadar M, Maranzano J, Bonnet A, Mayo NE, et al. HIV infection and cerebral small vessel disease are independently
400 associated with brain atrophy and cognitive impairment. *AIDS*. 2019;33(7):1197-205.

- 401 64. Sanford R, Ances BM, Meyerhoff DJ, Price RW, Fuchs D, Zetterberg H, et al. Longitudinal Trajectories of Brain Volume and Cortical Thickness
402 in Treated and Untreated Primary Human Immunodeficiency Virus Infection. *Clinical infectious diseases : an official publication of the Infectious*
403 *Diseases Society of America*. 2018;67(11):1697-704.
- 404 65. Sanford R, Fernandez Cruz AL, Scott SC, Mayo NE, Fellows LK, Ances BM, et al. Regionally Specific Brain Volumetric and Cortical Thickness
405 Changes in HIV-Infected Patients in the HAART Era. *Journal of acquired immune deficiency syndromes*. 2017;74(5):563-70.
- 406 66. Blackstone K, Moore D, Heaton R, Franklin Jr D, Woods S, Clifford D, et al. Diagnosing symptomatic HIV-associated neurocognitive
407 disorders: self-report versus performance-based assessment of everyday functioning. *Journal of the International Neuropsychological Society:*
408 *JINS*. 2012;18(1).
- 409 67. Sorstedt E, Nilsson S, Blaxhult A, Gisslen M, Flamholz L, Sonnerborg A, et al. Viral blips during suppressive antiretroviral treatment are
410 associated with high baseline HIV-1 RNA levels. *BMC infectious diseases*. 2016;16:305.
- 411 68. Sacktor N, McDermott MP, Marder K, Schifitto G, Selnes OA, McArthur JC, et al. HIV-associated cognitive impairment before and after the
412 advent of combination therapy. *Journal of neurovirology*. 2002;8(2):136-42.
- 413 69. Wojna V, Skolasky RL, Hechavarria R, Mayo R, Selnes O, McArthur JC, et al. Prevalence of human immunodeficiency virus-associated
414 cognitive impairment in a group of Hispanic women at risk for neurological impairment. *Journal of neurovirology*. 2006;12(5):356-64.
- 415 70. De Francesco D, Underwood J, Post FA, Vera JH, Williams I, Boffito M, et al. Defining cognitive impairment in people-living-with-HIV: the
416 POPPY study. *BMC infectious diseases*. 2016;16(1):617.
- 417 71. Su T, Schouten J, Geurtsen GJ, Wit FW, Stolte IG, Prins M, et al. Multivariate normative comparison, a novel method for more reliably
418 detecting cognitive impairment in HIV infection. *AIDS*. 2015;29(5):547-57.
- 419 72. Underwood J, De Francesco D, Leech R, Sabin CA, Winston A, Pharmacokinetic, et al. Medicalising normality? Using a simulated dataset to
420 assess the performance of different diagnostic criteria of HIV-associated cognitive impairment. *PloS one*. 2018;13(4):e0194760.
- 421



Method A: Lowest score per domain is > 1 S.D. below norms

Method B: Lowest score per domain is > 1.5 S.D. below norms

Method C: Average of all z-scores \geq 1.5 S.D. below norms

Method D: 1 > 1.5 S.D. below norms or 2 tests > 1. S.D. below norms